Full Press Release Details
We hosted a virtual investor event, showcasing the data and strategic updates on our Nu.Q ® platform for cancer detection and monitoring.
Led by Chief Commercial Officer Gael Forterre , Chief Medical Officer Dr. Andrew Retter , and Chief Scientific Officer Dr. Jake Micallef , the event highlighted the completion of several large independent studies that further validated the clinical utility of Nu.Q ® assays.
Key takeaways included:
• A detailed look at Volition’s commercialization progress , including developments in both licensing and sales channels.
• Insight into the role of Nu.Q ® in lung cancer care , from early screening through to monitoring treatment response and disease progression—addressing a potential $4 billion market .
• Presentation of data (currently under peer review) showing that Nu.Q ® can detect multiple common cancers —including lung, breast, prostate, colon, and liver—with an overall AUC of 86% and very low false positive rates, underscoring its potential to disrupt the $20 billion U.S. liquid biopsy market for multi-cancer early detection.
A detailed look at Volition’s commercialization progress , including developments in both licensing and sales channels.
Insight into the role of Nu.Q ® in lung cancer care , from early screening through to monitoring treatment response and disease progression—addressing a potential $4 billion market .
Presentation of data (currently under peer review) showing that Nu.Q ® can detect multiple common cancers —including lung, breast, prostate, colon, and liver—with an overall AUC of 86% and very low false positive rates, underscoring its potential to disrupt the $20 billion U.S. liquid biopsy market for multi-cancer early detection.
The event concluded with an interactive Q&A session, reflecting strong interest from the investor community in Volition’s mission and momentum.
Volition continues to lead in the field of epigenetics, developing accessible and cost-effective blood-based diagnostics with the potential to transform early detection and disease monitoring worldwide.
Be the first to hear about Volition’s latest breakthroughs, clinical milestones, and investor updates: sign up for our email newsletter .
Related Articles
• Events Join Volition Veterinary at Netherlands Vet
• Blog Celebrating Women in Science: Insights from the women working in science at Volition
Join Volition Veterinary at Netherlands Vet
Celebrating Women in Science: Insights from the women working in science at Volition
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields